

CORRECTION


Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer

Sherene Loi, Stefan Michiels, Jose Baselga, John M. S. Bartlett, Sandeep K. Singhal, Vicky S. Sabine, Andrew H. Sims, Tarek Sahmoud, J. Michael Dixon, Martine J. Piccart, Christos Sotiriou

The following information is missing from the Competing Interests statement: JB is a consultant to Novartis, Roche, Merck, Sanofi-Aventis, Verastem, Bayer, Chugai, Exelixis, Onyx and Constellation.

Reference

1. Loi S, Michiels S, Baselga J, Bartlett JMS, Singhal SK, Sabine VS, et al. (2013) PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer. PLoS ONE 8(1): e53292. <https://doi.org/10.1371/journal.pone.0053292> PMID: 23301057



OPEN ACCESS

Citation: Loi S, Michiels S, Baselga J, Bartlett JMS, Singhal SK, Sabine VS, et al. (2019) Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer. PLoS ONE 14(4): e0216175. <https://doi.org/10.1371/journal.pone.0216175>

Published: April 23, 2019

Copyright: © 2019 Loi et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.